Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity

Gautam K. Bandyopadhyay1 and Sushil K. Mahata1,2*

1Department of Medicine, University of California San Diego, La Jolla, CA, USA, 2Department of Medicine, Metabolic Physiology and Ultrastructural Biology Laboratory, VA San Diego Healthcare System, San Diego, CA, USA

Chromogranin A (CgA) is a prohormone and granulogenic factor in endocrine and neuroendocrine tissues, as well as in neurons, and has a regulated secretory pathway. The intracellular functions of CgA include the initiation and regulation of dense-core granule biogenesis and sequestration of hormones in neuroendocrine cells. This protein is co-stored and co-released with secreted hormones. The extracellular functions of CgA include the generation of bioactive peptides, such as pancreastatin (PST), vasoostatin, WE14, catestatin (CST), and serpinin. CgA knockout mice (Chga-KO) display: (i) hypertension with increased plasma catecholamines, (ii) obesity, (iii) improved hepatic insulin sensitivity, and (iv) muscle insulin resistance. These findings suggest that individual CgA-derived peptides may regulate different physiological functions. Indeed, additional studies have revealed that the pro-inflammatory PST influences insulin sensitivity and glucose tolerance, whereas CST alleviates adiposity and hypertension. This review will focus on the different metabolic roles of PST and CST peptides in insulin-sensitive and insulin-resistant models, and their potential use as therapeutic targets.

Keywords: obesity, insulin resistance, inflammation, chromogranin A knockout, pancreastatin, catestatin

INTRODUCTION

The human chromogranin A (gene, CHGA; protein, CgA) gene encodes a 439-amino-acid mature protein of approximately 48–52 kDa with a coiled-coil structure (1–6). Initially detected in chromafin granules of the adrenal medulla, this evolutionarily conserved protein is ubiquitously distributed in secretory vesicles of endocrine, neuroendocrine, and neuronal cells. CgA plays a pivotal role in the initiation and regulation of dense-core secretory granule biogenesis and hormone sequestration at the trans-Golgi network in neuroendocrine cells (4, 7–9). Increased levels of CgA have been identified in the blood of patients suffering from carcinoids or other neuroendocrine tumors (10–14), heart failure, renal failure, hypertension, rheumatoid arthritis, and inflammatory bowel disease (15–23), indicating an important role of CgA to influence human health and disease (24). Structurally, CgA has 8–10 dibasic sites and is proteolytically cleaved by prohormone convertases (25–27), cathepsin L (28), plasmin (29, 30), and kallikrein (31), generating biologically active peptides including the dysglycemic peptide pancreastatin (PST) (CgA 250–301) (32, 33); WE14 (hCgA 324–337) which acts as the antigen for highly diabetogenic CD4+ T cell clones (34–38); the vasodilating, antiadrenergic, and antiangiogenic peptide vasostatin 1 (CgA 1–76) (39–43); the antiadrenergic, antihypertensive, antibacterial, proangiogenic, and antiobesigenic peptide catestatin (CST) (CgA 352–372) (44–56); and the proadrenergic peptide serpinin (CgA 402–439) (57, 58). Several of these CgA-derived peptides...
have opposing counter-regulatory effects. For example, cardiac contractility in rodents is controlled by vasostatin (hCgA1–76) and CST (hCgA352–372), which are antiadrenergic (51, 59) as well as serpinin (hCgA402–439), which is proadrenergic (58) (Figure 1A).

Likewise, angiogenesis is controlled by vasostatin acting in an antiangiogenic manner (43, 56) and CST acting as in a proangiogenic manner (50, 56). These CgA-derived peptides, with diverse functions, emphasize the importance of the CgA proprotein in the regulation of physiological functions (Figure 1A).

Accordingly, Chga whole-body knockout mice present a complex set of metabolic phenotypes and are obese, hyperadrenergic, and hypertensive (48, 60–63). Chga-KO mice have become an important model to study the roles of individual CgA-derived peptides through analysis of phenotypes after supplementation (48, 55, 60, 61, 64). Here, we will focus on how two of these peptides, PST and CST, act as important modulators of insulin sensitivity and glucose metabolism.

**PST INHIBITS GLUCOSE-STIMULATED INSULIN SECRETION (GSIS)**

PST, a C-terminally glycine-amidated 49-mer peptide, was identified in 1986 as a potent inhibitor of glucose-stimulated insulin secretion (GSIS) (32). Two molecular forms were detected in human plasma: a 52 amino acid form (CgA250–301) and a larger...
form with a molecular weight of 15–21 kDa (65). Although the PST sequence is well conserved in mammals, showing 41.5% homology between humans and the Tasmanian devil, no homology could be detected in submammalian vertebrates (Figure 1B) (66–68). PST inhibits GSIS \textit{in vivo} in mice, rats, dogs, and pigs, as well as \textit{in vitro} from isolated rat islets (69). In the perfused rat pancreas, PST inhibits unstimulated and stimulated insulin secretion (70–73). In PST-deficient \textit{Chga}-KO mice, GSIS was ~1.7-fold higher at 7 and 15 min after administration of glucose, confirming the inhibitory role of PST in GSIS (60). In addition, PST inhibits glucagon secretion induced by low glucose (74) but had no effect on somatostatin secretion (75). In addition to inhibition of GSIS, PST inhibits insulin-stimulated glucose transport in primary rat and mouse adipocytes (60, 76, 77), differentiated 3T3-L1 adipocytes (68, 78), and primary hepatocytes (60). PST also increases nitric oxide (NO) levels in

**FIGURE 2** (A) Schematic representation of the role of pancreaticatin (PST) in the regulation of insulin secretion from pancreatic beta cells. PST-induced nitric oxide (NO) production, following a guanylate cyclase-cGMP-NOS pathway, inhibits glucose-stimulated insulin secretion (GSIS). (B) Schematic diagram showing PST inhibition of gluconeogenesis in hepatocytes. PST initiates a GTP-binding protein linked signaling cascade leading to activation of diacylglycerol (DAG) and calcium-dependent conventional PKC (cPKC), which attenuates IRS–PI3K–PDK1–AKT signaling pathway. In addition, stimulation of the cGMP–NOS pathway also assaults this signaling pathway by nitrolyiation of IRS. Thus, PST-mediated suppression of this pathway allows forkhead box protein O1 (FoxO1) and sterol regulatory element-binding transcription factor 1c (SREBP1c) to stimulate expression of gluconeogenic genes, phosphoenolpyruvate carboxykinase 1 (Pck1) (also known as \textit{G6pc} gene). and thus prevent insulin action. Under control conditions, insulin would have activated this signaling pathway, causing phosphorylation of FoxO1 (promoting its exclusion from the nucleus) and preventing processing of SREBP1 proprotein to SREBP1c with consequent inhibition of expression of gluconeogenic genes and gluconeogenesis. (C) Catexatin (CST) stimulation of lipolysis in adipocytes. Activation of \( \alpha_2 \)-adrenergic receptor (\( \alpha_2 \)-AR) inhibits \( \beta_1/2 \)-AR-induced lipolysis in a dominant way in obesity. CST enhances lipolysis by inhibiting \( \alpha_2 \)-AR, which promotes \( \beta_1/2 \)-AR action and the consequent downstream signaling. Hormone-sensitive lipase (HSL) is an intracellular, neutral lipase that has broad substrate specificity, catalyzing the hydrolysis of triacylglycerol (TAG), diacylglycerol (DAG), monoacylglycerol (MAG), and cholesteryl esters. Its activity against DAG is about 10- and 5-fold higher than its activity against TAG and MAG, respectively, whereas its activity against cholesteryl esters is about twice its activity toward TAG. The hydrolytic activity of HSL against TAG and cholesteryl esters, but not against DAG, is stimulated by phosphorylation mediated primarily by PKA (64). AC, adenylyl cyclase; FFA, free fatty acids; MGL, monoacylglycerol lipase; PKA, protein kinase A. (D) Summary of PST and CST actions.
HTC rat hepatoma cells (79), L6 myotubes (68), and in livers of Chga-KO mice (60), showing that PST inhibits insulin action. Since NO inhibits GSIS (80) and PST increases NO production (60, 68, 79), we believe that PST likely inhibits GSIS through activation of the NO pathway (Figure 2A).

### PST REGULATES HEPATIC GLUCOSE METABOLISM

PST treatment inhibits insulin-stimulated glycogen synthesis in primary hepatocytes (81) and activates glycogenolysis in the rat liver, implicating a direct anti-insulin effect on liver metabolism (82, 83). PST-deficient Chga-KO mice show greater suppression of hepatic glucose production (HGP) compared to wild-type (WT) mice during insulin clamp studies (60). Decreased glucose production in Chga-KO mice was also supported by decreased glucose production during pyruvate tolerance tests and decreased mRNA transcript levels of the gluconeogenic genes, such as the phosphoenolpyruvate carboxykinase 1 and glucose-6-phosphatase (G6pc), compared to WT mice that were restored to WT levels after supplementation of PST to Chga-KO mice (60). PST activates gluconeogenesis by decreasing phosphorylation of insulin receptor substrate 2 at tyrosine residues through activation of conventional PKC and increases production of NO with subsequent attenuated phosphorylation of protein kinase B (AKT), forkhead box protein O1, and reduced matured sterol regulatory element-binding transcription factor 1c (SREBP1c) (Figure 2B) (60). These findings are consistent with the anti-insulin action of PST.

### PST INFLUENCES LIPID METABOLISM

In addition to glucose metabolism, PST also modulates lipid metabolism. PST decreases insulin-stimulated synthesis of lipids in rat adipocytes (85), which is consistent with the PST-dependent increased expression of hepatic lipogenic genes in Chga-KO mice, including Srebp1c, peroxisome proliferator-activated receptor-gamma, and glycerol-3-phosphate acyltransferase (Gpat) (60). PST also stimulates release of glycerol and free fatty acids from rat adipocytes, which is completely inhibited by insulin (85). In humans, PST augments free fatty acid efflux into the circulation, resulting in an overall spillover of ~4.5-fold, which is consistent with the reported lipolytic action of PST (85), confirming the anti-insulin effects of PST.

### PST PROMOTES INFLAMMATION AND INSULIN RESISTANCE

Since PST inhibits the action of insulin on glucose and lipid metabolism, one would expect improved insulin sensitivity in PST-deficient mice. Indeed, Chga-KO mice show improved hepatic insulin sensitivity as assessed by insulin tolerance tests (ITTs) showing increased hypoglycemia, and insulin clamp studies showing increased suppression of HGP. Improved hepatic insulin sensitivity was abolished when Chga-KO mice were treated with PST, implicating a positive correlation between PST and the development of insulin resistance (60). Similarly, type 2 diabetes mellitus (T2DM) patients show a substantial increase in plasma PST levels (~3.7-fold) (77). Gestational diabetic subjects and patients with non-insulin-dependent diabetes mellitus also show increased plasma PST levels (86, 87).

Feeding mice a high fat diet (HFD) creates obesity, leading to hyperinsulinemia and inflammation (88–92). ITT studies revealed that HFD-fed Chga-KO mice displayed improved insulin sensitivity compared to WT mice, demonstrating the importance of PST in the development of IR (64). This was reinforced by hyperinsulinemic–euglycemic clamp studies, where Chga-KO–HFD mice displayed increased glucose infusion rates, higher insulin-stimulated glucose disposal rates (IS-GDRs), and suppressed HGP. Recent studies implicate dissociation between obesity and insulin resistance as long as the inflammation is suppressed (64). The presence of supraphysiological levels of PST can reconnect obesity with insulin resistance by introducing inflammation. In the absence of PST, animals are insulin sensitive despite obesity. This is reminiscent of rosiglitazone-treated WT-HFD mice, which are insulin sensitive but obese (93–95). The hallmarks of insulin resistance in HFD mice are obesity, hyperinsulinemia, and increased inflammation (88–92). Suppression of inflammation in HFD mice can improve insulin sensitivity (93–95). Therefore, the resistance to diet-induced insulin resistance in Chga-KO mice may reflect less inflammation. In the absence of PST, animals are insulin sensitive despite obesity. This is reminiscent of rosiglitazone-treated WT-HFD mice, which are insulin sensitive but obese (93–95).

The hallmarks of insulin resistance in HFD mice are obesity, hyperinsulinemia, and increased inflammation (88–92). Suppression of inflammation in HFD mice can improve insulin sensitivity (93–95). Therefore, the resistance to diet-induced insulin resistance in Chga-KO mice may reflect less inflammation. In the absence of PST, animals are insulin sensitive despite obesity. This is reminiscent of rosiglitazone-treated WT-HFD mice, which are insulin sensitive but obese (93–95). The hallmarks of insulin resistance in HFD mice are obesity, hyperinsulinemia, and increased inflammation (88–92). Suppression of inflammation in HFD mice can improve insulin sensitivity (93–95). Therefore, the resistance to diet-induced insulin resistance in Chga-KO mice may reflect less inflammation. In the absence of PST, animals are insulin sensitive despite obesity. This is reminiscent of rosiglitazone-treated WT-HFD mice, which are insulin sensitive but obese (93–95). The hallmarks of insulin resistance in HFD mice are obesity, hyperinsulinemia, and increased inflammation (88–92). Suppression of inflammation in HFD mice can improve insulin sensitivity (93–95). Therefore, the resistance to diet-induced insulin resistance in Chga-KO mice may reflect less inflammation. In the absence of PST, animals are insulin sensitive despite obesity. This is reminiscent of rosiglitazone-treated WT-HFD mice, which are insulin sensitive but obese (93–95).
insulin sensitivity in lean Chga-KO mice was reversed by HFD feeding as demonstrated by improved IS-GDR in muscle of HFD-fed Chga-KO mice. Can feeding a high amount of lipids to CgA-deficient mice regenerate cells and repair muscle dysfunction? What kind of lipid could that be? These unorthodox results on the regulation of muscle insulin sensitivity by a CgA-derived protein need further investigation. In this regard, one provocative speculation may deserve some investigation. HFD-induced ceramide and sphingolipids were implicated in the mobilization and differentiation of bone marrow-derived stem/progenitor cells, which are involved in the repair of tissues in ischemic heart disease (96). More specifically, sphingosine-1-phosphate (S1P) acts as a trophic factor for skeletal muscle cell regeneration (97). Sphingolipids are important structural components of cell membranes and are derived from ceramide. Ceramide production is increased in obesity and after HFD feeding (98, 99). Ceramide can be deacylated to sphingosine, which is then phosphorylated by sphingosine kinases to yield S1P. Since this improvement in muscle insulin sensitivity by HFD happened in Chga-KO mice, not in WT-DIO mice, absence of CgA protein or peptides triggered this unusual phenomenon. Therefore, it will be very important to investigate the roles of these dietary lipids in muscle repair and the functional relationship of these lipids with the CgA protein and CgA-derived peptides. Alternatively, it is also possible that the absence of CgA protein and its derivatives stimulated release of some myokines in response to dietary lipids, which would otherwise remain suppressed in WT-DIO mice. This response to HFD in Chga-KO mice could be muscle specific because muscle expresses CgA (100), and liver and adipose tissue do not (3, 46). Effects of CgA deficiency on liver and adipose tissue may be more systemic in nature, a part of which is carried out by CgA-deficient macrophages (64).

**PST PROMOTES ENDOPLASMIC RETICULUM (ER) STRESS BY ATTENUATING EXPRESSION OF Grp78**

The accumulation of unfolded and misfolded proteins in the ER lumen, termed ER stress, leads to activation of signaling pathways to counteract defects in protein folding (101–106). This unfolded protein response (UPR) increases repair activities, reduces global protein synthesis, and activates ER-associated protein degradation. However, if ER stress becomes chronic and UPR cannot cope with the repair demands, protein-folding homeostasis breaks down, leading to activation of apoptotic pathways (103, 107, 108). Thus, ER stress and the UPR play important roles in the pathogenesis of multiple human metabolic diseases including insulin resistance, diabetes, obesity, non-alcoholic fatty liver disease, and atherosclerosis (109, 110). The immunoglobulin binding protein (BiP) [also called glucose-regulated protein 78 (Grp78)], is an ER chaperone that is required for protein folding. BiP/Grp78 is a peptide-stimulated ATPase of the Hsp70 family that prevents protein aggregation by stabilizing intermediates in the protein-folding process.

Using ligand affinity chromatography with biotinylated human PST (hCgA273–301-amide) as “bait” on a murine liver homogenate (as “prey”), we found that PST interacts in a pH-dependent fashion with Grp78 (78). Whereas NCD-fed Chga-KO livers show increased expression of Grp78, PST caused dose-dependent inhibition of Grp78 ATPase activity and inhibited increased expression of Grp78 during UPR activation (by tunicamycin) in hepatocytes (78). In hepatocytes, PST increased expression of G6pc. These results indicate that a major hepatic target of PST is the adaptive UPR chaperone Grp78 and that ATPase activity associated with Grp78 is involved in the suppression of glucose production by attenuating G6pc expression (78). Grp78s ATPase activity is required to suppress expression of G6pc; ER stress and suppression of glucose utilization appear to augment Grp78 expression (111). Although it is not clear how circulating PST might contact the ER luminal protein Grp78 to modulate ER and insulin action, it has been reported that Grp78 translocates to the cell surface under some pathological conditions (112, 113).

**MODULATION OF METABOLISM BY NATURALLY OCCURRING VARIANTS OF PST**

Single-nucleotide polymorphism analysis of PST, both in vivo and in vitro, showed greater inhibition of insulin-stimulated glucose uptake by Gly297Ser variants followed by the Glu287Arg variants compared to WT-PST (77). The in vitro studies also revealed increased expression of gluconeogenic genes by PST variants as compared to WT-PST, with comparable potencies by Glu287Arg and Gly297Ser variants (68). The Gly297Ser subjects displayed markedly elevated plasma glucose and cholesterol compared to the Gly297Gly individuals. Interestingly, whereas the variants of PST in the C-terminal half of the molecule at 287 (Glu287Arg) and at 297 (Gly297Ser) enhance anti-insulin effects and elevate plasma glucose by inhibition of glucose uptake and stimulation of gluconeogenic effects, experimental deletion of the three N-terminal amino acids Pro–Glu–Gly on human WT-PST demonstrated the opposite effects by reducing plasma glucose level and hepatic gluconeogenesis in a rodent model of obesity (64). Therefore, finding variants in the N-terminal end of PST among the human population may lead to discovery of an allele which would confer protection against insulin resistance and can be used as an insulin-sensitizing peptide such as a N-terminal variant of PST (lacking three amino acids from the N-terminal end) called PSTv1 (64).

**REGULATION OF INSULIN SENSITIVITY BY THE PST ANTAGONIST PSTv1**

The elevated levels of plasma PST observed in T2DM patients (77) implied that preventing PST action might serve a therapeutic purpose of controlling insulin resistance and diabetes. To demonstrate a direct in vivo role of PST in the regulation of insulin sensitivity, WT-HFD mice were injected with the PST variant, PSTv1, which is a competitive antagonist of native PST. PSTv1 lacks the first three N-terminal residues of native PST and blocks
PST-mediated inhibition of glucose uptake and leptin secretion in 3T3-L1 preadipocytes. As predicted, chronic PSTv1 treatment lowered fasting plasma glucose levels in WT-HFD mice and improved glucose tolerance and insulin sensitivity (64). These results suggested that in WT-HFD mice, where the level of PST is high, PSTv1 administration competes with the native PST and phenocopies Chga-KO mice. This demonstrates the potential of PST as a therapeutic target for treatment of insulin resistance and diabetes.

**CST DECREASES HYPERTENSION AND OBESITY**

Hypertensive patients show elevated levels of plasma CgA but decreased plasma CST (114, 115). Low plasma CST predicts augmented pressor responses to environmental stimuli (114). In rats, CST reduces blood pressure responses to activation of sympathetic outflow by electrical stimulation (116). This vasodepressor effect of CST was mediated by massive release of histamine with subsequent vasodilation by histamine-induced production of NO. CST is a potent endogenous inhibitor of catecholamine secretion (44–47, 117–120) and catecholamine-mediated hypertension (48, 121). Chga-KO mice showed hyperadrenergic and hypertensive phenotypes that were normalized by intraperitoneal administration of CST (48). CSTs hypotensive effect was also documented in a polygenic model of high blood pressure mice (121). Other studies showed that CST also provides cardioprotection by inhibiting the opening of the mitochondrial permeability transition pore and stimulating the reperfusion injury salvage kinase pathway (122–127).

Catestatin-deficient Chga-KO mice are obese on an NCD (48). Chronic CST administration to Chga-KO mice reduced epididymal fat pad size to WT level (~25% reduction with respect to body weight of Chga-KO mice) (55). CST decreased plasma triglyceride levels in Chga-KO mice by increasing lipolysis (increased plasma glycerol and non-esterified fatty acids) through inhibition of α2-adrenergic receptor (α2-AR) (Figure 2C) (55). While inhibition of α2-AR by CST indirectly facilitates β-AR mediated lipolysis, CST can also have direct effect on ATGL (adipose triacylglycerol lipase) and HSL (hormone sensitive lipase) via activation of AMPK (128) as it has been demonstrated that activation of AMPK promote lipolysis in adipose tissue through ATGL and HSL. CST-treated Chga-KO mice show increased palmitate oxidation but decreased incorporation into lipids, which indicates that CST inhibits expansion of adipose tissue but promotes fatty acid uptake in the liver for oxidation. CST induced expression of several fatty acid oxidation genes including carnitine palmitoyltransferase 1a, peroxisome proliferator-activated receptor-a, acyl-CoA oxidase 1, and uncoupling protein 2, supporting increased fatty acid oxidation in the liver. In addition, CST increased expression of the fatty acid transporter gene Cd36 and the lipogenic gene glyceraldehyde-3-phosphate acyltransferase 4 (Gpat4), indicating that CST stimulates fatty acid incorporation into triglycerides but not de novo lipogenesis. Overall, CST promoted lipid flux from the adipose tissue toward the liver for β-oxidation (55). These obesity-reducing effects of CST are mediated by inhibition of α2-AR signaling and enhancement of leptin receptor signaling. In contrast to the negative metabolic effects of PST, CST has beneficial effects that could be utilized in therapeutic treatment of hypertension and obesity.

**CONCLUSION AND FUTURE PERSPECTIVES**

Chromogranin A is one of the few protein molecules, which can be processed into both negative and positive regulators such as PST and CST for fine-tuning and maintaining metabolic homeostasis. With respect to the pathway to lipid disposal, studies on the direct effect of CST, through activation of AMPK, on lipolytic activities of ATGL and HSL may generate exciting information. Although the metabolic effects of PST and CST have been well investigated, how they transmit signals into cells remains to be determined. Are there specific receptors for these peptides? Alternatively, can they opportunistically bind to some non-specific BiPs on the cell surface and get endocytosed? In some cells such as neutrophils, CST has been shown to be permeable (53). With respect to PST, its binding to Grp78 may occur opportunistically on the cell surface when Grp78, usually a luminal protein, translocates to the cell surface, which occurs under some pathological conditions (112, 113). Whether such interaction happens or not should be a matter of future investigation. If that happens, Grp78 would be able to carry PST to the luminal compartment and initiate a reaction with a small G-protein binding molecule leading to a cascade described in Figure 2B. In addition, although PST has been established as an anti-insulin peptide, the mechanisms underlying PST-dependent regulation of insulin secretion are poorly understood. Other CgA-derived pro-insulin peptides may also exist and need to be further investigated. These efforts, as well as generation of PST antagonists, may lead to development of powerful therapeutic treatments for insulin resistance and diabetes. Beyond PST and CST, additional studies should shed light on the role of other CgA-derived peptides in metabolism, with implications for treatment of metabolic disease.

**AUTHOR CONTRIBUTIONS**

SM conceived the idea. GB and SM contributed equally to researching the data and writing of the manuscript.

**ACKNOWLEDGMENTS**

The authors thank Sumana Mahata for editing the review article.

**FUNDING**

There is no financial support from funding organization. The research was supported by Mahata’s home equity loan.
REFERENCES

1. Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem (1987) 262(35):17260–30.

2. Mouland AJ, Bevan S, White JH, Hendy GN. Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. J Biol Chem (1994) 269(9):6918–26.

3. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience (1992) 49(3):497–528. doi:10.1016/0306-4522(92)90222-N

4. Jacangelo AE, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept (1995) 58(3):65–88. doi:10.1016/0306-4522(95)00069-N

5. Iacangelo AL, Eiden LE. Chromogranin A induced Golgi coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. Biochemistry (2007) 46(38):10999–1012. doi:10.1021/bi700704r

6. Kim T, Tao-Cheng J, Iden LE, Loh YP. Chromogranin A, an “on/off” switch controlling dense-core secretory granule biogenesis. Cell (2001) 106(4):499–509. doi:10.1016/S0092-8674(01)00459-7

7. Kim T, Tao-Cheng J, Iden LE, Loh YP. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol (2014) 49(8):942–9. doi:10.3109/00365521.2014.929910

8. Loi VP, Cheng Y, Mahata SK, Corti A, Tota B. Chromogranin A and derived peptides in health and disease. J Mol Neurosci (2012) 48(2):347–56. doi:10.1007/s12031-012-9728-2

9. Netz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem (1993) 217(1):247–57. doi:10.1111/j.1342-1033.1993.tb18240.x

10. Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothisrikul S, et al. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem (2000) 275(30):22905–15. doi:10.1074/jbc.M001232200

11. Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothisrikul S, et al. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin A into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry (2003) 42(23):6936–46. doi:10.1021/bi0300433

12. Bandyopadhyay S, Rodriguz-Flores J, Nunez S, Olson NH, Yaingkang SM, et al. Biogenesis of the secretory granule: chromogranin A coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. Biochemistry (2007) 46(38):10999–1012. doi:10.1021/bi700704r

13. Elias S, Delestre C, Cory S, Marais S, Courel M, Vazquez-Martinez R, et al. Chromogranin A induces the biogenesis of granules with calcium- and actin-dependent dynamics and exocytosis in constitutively secreting cells. Endocrinology (2012) 153(9):4444–56. doi:10.1210/en.2012-1436

14. O’Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in human cancer patients. Clin Chem (1989) 35(8):1631–7. doi:10.1093/clinchem/35.8.1631

15. Rosjo H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, et al. Chromogranin-A production and fragmentation in patients with Takayasu arteritis. Arthritis Res Ther (2016) 18:187. doi:10.1186/s13075-016-1082-2

16. O’Connor DT, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, et al. Chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis (2009) 15(6):867–71. doi:10.1002/ibd.20851

17. Zissimopoulos A, Vrabelis S, Konialis M, Chadolias D, Bampali A, Constantindis T, et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol (2014) 49(8):942–9. doi:10.3109/00365521.2014.929910

18. Bandyopadhyay S, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem (1987) 262(35):17260–30.

19. O’Connor DT, Taupenot L, Biswas N, Taulane JP, Olson NH, Vaingankar SM, et al. Biogenesis of the secretory granule: chromogranin A coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. Biochemistry (2007) 46(38):10999–1012. doi:10.1021/bi700704r

20. Bandyopadhyay S, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem (1987) 262(35):17260–30.

21. Bandyopadhyay S, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem (1987) 262(35):17260–30.
agonists in type 1 diabetes. Proc Natl Acad Sci USA (2015) 112(43):13318–23. doi:10.1073/pnas.1517862112
39. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept (1992) 41(1):9–18. doi:10.1016/0167-0115(92)90509-S
40. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol (1993) 5(4):405–12. doi:10.1111/j.1365-2826.1993.tb00501.x
41. Tota B, Mazza R, Angelone T, Nullans G, Metz-Boutique MH, Aunis D, et al. Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul Pept (2003) 114(2–3):123–30. doi:10.1016/S0167-0115(03)00112-5
42. Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, Tota B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiotatins on the isolated working frog heart. Gen Comp Endocrinol (2004) 136(2):217–24. doi:10.1016/j.ygcen.2003.12.012
43. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med (1998) 188(12):2349–56. doi:10.1084/jem.188.12.2349
44. Mahata SK, O’Connor DT, Mahata M, Wang TC, Kennedy BP, Ziegler MG, et al. Calotatin A secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promotor/phopptophor reporter and inhibition of secretion and transcription by the chromogranin A fragment catstatin. J Biol Chem (2003) 278:32058–67. doi:10.1074/jbc.M303554200
45. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, et al. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of calotatinne physiology. Am J Hum Genet (2004) 74(2):197–207. doi:10.1086/381399
46. Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest (2005) 115(7):1942–52. doi:10.1172/JCI24343
47. Hattori A, Wu JD, Mahata SK, Gonthier B, Bagnard D, Chasserot-Golaz S, et al. Novel antinociceptive activity for the catecholamine release-inhibitory peptide catstatin. J Biol Chem (2005) 280:28498–509. doi:10.1074/jbc.M104008500
48. Bartolomucci A, Quintieri AM, Pastua T, Gentile S, Tota B, Mahata SK, et al. Serpin factor yield cardiovascular instability and hypertension in the chromogranin A null mouse. Endocrinology (2009) 150(11):5027–35. doi:10.1210/en.2009-0429
49. Gayen JR, Zhang K, Ramachandrarao SP, Mahata M, Chen Y, Kim H-S, et al. Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin A gene. Circ Cardiovasc Genet (2010) 3:414–25. doi:10.1161/CIRCGENETICS.109.924050
50. Dev NB, Gayen JR, O’Connor DT, Mahata SK. Chromogranin A and the automatic system: decomposition of heart rate variability by time and frequency domains, along with non-linear characteristics during chromogranin A ablation, with “rescue” by its catstatin. Endocrinology (2010) 151:2760–8. doi:10.1210/en.2009-1110
51. Gayen JR, Jiang Z, Ramachandrarao SP, Mahata M, Chen Y, Kim H-S, et al. Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes (2015) 64(1):104–16. doi:10.2337/db13-1747
52. Kitayama N, Tateishi K, Funakoshi A, Miyasaka K, Shimazoe T, Kono A, et al. Pancreastatin molecular forms in normal human plasma. Life Sci (1994) 54(21):1571–8. doi:10.1016/0369-8031(94)90208-9
53. Bartolomucci A, Quintieri AM, Pastua T, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endor Rev (2011) 32(6):755–97. doi:10.1210/er.2010-00027
54. Valicherla GR, Hossain Z, Mahata SK, Gayen JR. Pancreastatin is an endogenous peptide that regulates glucose homeostasis. Physiol Genomics (2013) 45(22):1060–71. doi:10.1152/physiogenomics.00131.2013
55. Allu PK, Chirasani VR, Ghosh D, Mani A, Bera AK, Maji SK, et al. Naturally occurring variants of the dysglycemic peptide pancreastatin: differential potencies for multiple cellular functions and structure–function correlation. J Biol Chem (2014) 289(7):4455–69. doi:10.1074/jbc.M113.529016
56. Ahren B, Bertrand G, Royle M, Ribes G. Pancreastatin regulates glucose-stimulated insulin secretion from the perfused rat pancreas. Acta Physiol Scand (1996) 158(1):63–70. doi:10.1111/j.1365-201X.1996.525S29100.x
57. Efendic S, Tatamoto K, Mutt V, Quan C, Chang D, Ostenson CG. Pancreastatin and islet hormone release. Proc Natl Acad Sci U S A (1997) 84(20):7257–60. doi:10.1073/pnas.84.20.7257
58. Peiro E, Miralles P, Silvestre RA, Villanueva ML, Marco J. Pancreastatin inhibits its insulin secretion as induced by glucagon, vasoactive intestinal peptide, gastric inhibitory peptide, and 8-cholecystokinin in the perfused rat pancreas. Metabolism (1989) 38(7):679–82. doi:10.1016/0026-0495(89)90107-8
59. Peiro E, Degano P, Silvestre RA, Marco J. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci (1991) 49(10):761–5. doi:10.1016/0024-3205(91)90109-O
60. Schmidt WE, Creutzfeldt W. Pancreastatin – a novel regulatory peptide? Acta Oncol (1991) 30(4):441–9. doi:10.3109/02841869109902399
Bandyopadhyay and Mahata

88. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. J Clin Endocrinol Metab (2005) 90(9):5145–52. doi:10.1210/jc.2005-0408

89. Zilberkrott JD, McCully BH, Brooks VL. Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. J Pharmacol Exp Ther (2012) 343(2):206–13. doi:10.1124/jpet.112.194738

90. Foryst-Ludwig A, Hartge M, Clemenz M, Sprang C, Hess K, Marx N, et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol (2010) 9:64. doi:10.1186/1475-2840-9-64

91. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, intercellular adhesion molecule-1, and risk of developing type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol (1991) 11(6):999–1004. doi:10.1161/01.ATV.11.6.999

92. Kiyosawa K, Tsuchiya Y, Matsuda M, Tsuchihashi J, Okada Y, Inoue Y, et al. Interleukin-6, C-reactive protein, and risk of developing type 2 diabetes mellitus. Diabetes Care (2004) 27(8):1900–5. doi:10.2337/diacare.27.8.1900

93. Funakoshi A, Tateishi K, Shinozaki H, Matsumoto M, Wakasugi H. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucosidase hydrolase activities in parallel with glucose-stimulated insulin secretion. J Endocrinol (2006) 190(3):681–93. doi:10.1677/joe.1.06890

94. Sanchez, V, Lucas M, Calvo JR, Goberna R. Glycogenolytic effect of pancreastatin in the rat in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab (2005) 90(9):5145–52. doi:10.1210/jc.2005-0408

95. Bandyopadhyay, B, Ray, G, Bandyopadhyay, G, Mahata, S, O’Connor, D. Discovery of a novel target for the dysregulogenic chondrogenin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism. PLoS One (2014) 9(1):e84132. doi:10.1371/journal.pone.0084132

96. Sanchez-Margalet V, Gonzalez-Yanes C, Najib S. Pancreastatin, a chondrogenin A-derived peptide, inhibits DNA and protein synthesis by producing a novel negative feedback effect of nuclear factor kappaB in HTC rat hepatoma cells. J Hepatol (2001) 35(1):80–5. doi:10.1053/jhep.2000.06307

97. Mosen H, Salehi A, Henningsson R, Lundquist I. Nitric oxide inhibits, and carbon monoxide activates, islet alpha-glucosidase hydrolyase activities in parallel with glucose-stimulated insulin secretion. J Endocrinol (2006) 190(3):681–93. doi:10.1677/joe.1.06890

98. Sanchez, V, Lucas M, Calvo JR, Goberna R. Glycogenolytic effect of pancreastatin in isolated rat hepatocytes is mediated by a cyclo-AMP-independent Ca(2+)-dependent mechanism. Biochem J (1992) 284(Pt 3):659–62. doi:10.1042/bj2840659

99. Sanchez, V, Calvo JR, Goberna R. Glycogenolytic effect of pancreastatin in the rat. Biosci Rep (1990) 10(1):87–91. doi:10.1042/bsr010087

100. Sanchez-Margalet V, Calvo JR, Goberna R. Glycogenolytic and hyperglycemic effect of 33-49 C-terminal fragment of pancreastatin in the rat in vivo. Diabetes (2010) 99(8):1288–94. doi:10.2337/db10-0972

101. Tang K, Pasqua T, Biswas A, Mahata S, Tang J, Tang A, et al. Muscle injury, impaired muscle function and insulin resistance in chondrogenin A knockout mice. J Endocrinol (2017) 232(2):137–53. doi:10.1530/joe-16-0370

102. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137–40. doi:10.1126/science.1128294

103. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Otdelem E, et al. Endoplasmic reticulum stress limits obesity, insulin action, and type 2 diabetes. Science (2004) 306(5695):457–61. doi:10.1126/science.1103160

104. Tan, C, Zilberkrott, JD, Zilberkrott, JS, Hotamisligil, GS. The role of endoplasmic reticulum in lipid homeostasis and stress signaling. Cell (2012) 15(5):623–34. doi:10.1016/j.cell.2012.03.007

105. O’Connor, D, Bandyopadhyay, B, Ray, G, Bandyopadhyay, G, Mahata, S, O’Connor, D. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137–40. doi:10.1126/science.1128294

106. O’Connor, D, Bandyopadhyay, B, Ray, G, Bandyopadhyay, G, Mahata, S, O’Connor, D. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137–40. doi:10.1126/science.1128294

107. O’Connor, D, Bandyopadhyay, B, Ray, G, Bandyopadhyay, G, Mahata, S, O’Connor, D. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137–40. doi:10.1126/science.1128294

108. Cao SS, Kaufman RJ. Unfolded protein response.

109. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. J Clin Invest (2009) 119(5):1201–15. doi:10.1172/JCI37007

110. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Hepatol (2010) 53(9):1491–1500. doi:10.1016/j.jhep.2010.06.032

111. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Hepatol (2010) 53(9):1491–1500. doi:10.1016/j.jhep.2010.06.032

112. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Hepatol (2010) 53(9):1491–1500. doi:10.1016/j.jhep.2010.06.032

113. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Hepatol (2010) 53(9):1491–1500. doi:10.1016/j.jhep.2010.06.032

114. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Hepatol (2010) 53(9):1491–1500. doi:10.1016/j.jhep.2010.06.032
in humans at genetic risk of hypertension. J Hypertens (2002) 20:1335–45. doi:10.1097/00004872-200207000-00020

115. O’Connor DT, Zhu G, Rao E, Taupenot L, Fung MM, Das M, et al. Heritability and genome-wide linkage in US and Australian twins identify novel genomic regions controlling chromogranin A: implications for secretion and blood pressure. Circulation (2008) 118(3):247–57. doi:10.1161/CIRCULATIONAHA.107.709105

116. Kennedy BP, Mahata SK, O’Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides (1998) 19(7):1241–8. doi:10.1016/S0196-9781(98)00086-2

117. Mahata SK, Mahata M, Parmer RJ, O’Connor DT. Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem (1999) 274(5):2920–8. doi:10.1074/jbc.274.5.2920

118. Herrero CJ, Ales E, Pintado AJ, Lopez MG, Garcia-Palomero E, Mahata SK, et al. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis. J Neurosci (2002) 22(2):377–88.

119. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, et al. The catecholamine release-inhibitory “catestatin” fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol (2004) 66(5):1180–91. doi:10.1124/mol.104.002139

120. Mahapatra NR, Mahata M, Mahata SK, O’Connor DT. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens (2006) 24(5):895–904. doi:10.1097/01.hjh.0000222760.99852.e0

121. Biswas N, Gayen J, Mahata M, Su Y, Mahata SK, O’Connor DT. Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension. Hypertension (2012) 60(6):1552–9. doi:10.1161/HYPERTENSIONAHA.112.202127

122. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol (2010) 30(8):1171–9. doi:10.1007/s10571-010-9598-5

123. Bissino E, Fornero S, Gallo MP, Ramella R, Mahata SK, Tota B, et al. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K–eNOS pathway in the myocardium. Cardiovasc Res (2011) 91(4):617–24. doi:10.1093/cvr/cvr129

124. Perrelli MG, Tullio F, Angotti C, Cerra MC, Angelone T, Tota R, et al. Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial K(ATP) channels and ROS signalling. Pflugers Arch (2013) 465:1031–40. doi:10.1007/s00424-013-1217-0

125. Penna C, Pasqua T, Amelio D, Perrelli MG, Angotti C, Tullio F, et al. Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K–Akt–GSK3beta pathway and preserving mitochondrial membrane potential. PLoS One (2015) 10(3):e0119790. doi:10.1371/journal.pone.0119790

126. Bassino E, Fornero S, Gallo MP, Gallina C, Femmino S, Levi R, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. J Hypertens (2006) 24(5):895–904. doi:10.1097/01.hjh.0000222760.99852.e0

127. Angelone T, Quintieri AM, Pasqua T, Filice E, Cantafio P, Scavello F, et al. The NO stimulator, catestatin, improves the Frank–Starling response in normotensive and hypertensive rat hearts. Nitric Oxide (2015) 50:10–9. doi:10.1016/j.niox.2015.07.004

128. Kim S-J, Tang T, Abbott M, Viscarra JA, Wang Y, Sul HS. AMPK phosphorylates desnutrin/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue. Mol Cell Biol (2016) 36:1961–76. doi:10.1128/MCB.00244-16

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Bandyopadhyay and Mahata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.